Ajay Gupta, MD
Neurology · Fort Wayne, INNPI 1487651873
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $284,122 of the $411,265 with a category attached, or 69.1%. 56 manufacturers reported payments, led by EMD Serono, Inc. at 41.3% of the total. Reporting peaked in 2019 at $110,310 and has fallen 59.9% since, to $44,273 in 2025. Among neurology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,164 payments — averaging $353.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$170K
- Sanofi$51K
- Bristol Myers Squibb$38K
- Johnson & Johnson$35K
- Genentech USA, Inc.$35K
- TG Therapeutics, Inc.$26K
- plus $57K from 50 others
Across 208 payments — averaging $9809.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$840K
- Sanofi$564K
- EMD Serono, Inc.$271K
- Genentech, Inc.$220K
- Biogen$77K
- Bristol Myers Squibb$58K
- plus $11K from 3 others
What the payments were for
- Consulting fees$62,26015%
- Speaking & faculty fees$284,12269%
- Travel & lodging$38,9639%
- Food & beverage$25,4496%
- Education$4710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$411,265 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 78 | $693,388 |
| RebifInterferon Beta-1a/Albumin | 28 | $374,988 |
| Teriflunomide | 80 | $125,091 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 14 | $124,552 |
| ZeposiaOzanimod Hydrochloride | 14 | $116,589 |
| CopaxoneGlatiramer Acetate | 16 | $93,604 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 24 | $86,198 |
| IngrezzaValbenazine Tosylate | 11 | $81,252 |
| NuedextaDextromethorphan Hbr/Quinidine | 25 | $41,287 |
| UbrelvyUbrogepant | 27 | $36,812 |
| Glatiramer Acetate | 13 | $19,925 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 15 | $12,100 |
| Dimethyl Fumarate | 51 | $11,025 |
| Dalfampridine ErDalfampridine | 48 | $10,944 |
| Emgality PenGalcanezumab-Gnlm | 11 | $10,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Rebif | $169,926 | $374,98828 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $12,469 | $116,58914 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $481 | $93,60416 claims |
| Grifols USA, LLCGamunex-C | $45 | $86,19824 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $180 | $81,25211 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $66 | $41,28725 claims |
| AbbVieUbrelvy | $1,183 | $36,81227 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $75 | $6,16069 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Indiana.
Other neurology in Fort Wayne
- Marlene BultemeyerFort Wayne$277K
- Andrea HallerFort Wayne$242K
- Paul LaterFort Wayne$132K
- Christopher VachonFort Wayne$27K
- William ConteMerrillville$1.2M
- Anthony SimchakLafayette$720K
- Mark JanickiLebanon$573K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
- Christopher WilsonAvon$283K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.